Britain and America have agreed to a key bilateral deal that will maintain zero duties on UK drug exports going into the US market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has agreed to increase expenditure on medicines through the NHS. This move ensures that duties on these key products will be held at nothing for a duration of 36 months.
This deal is in response to previous statements to hike duties on branded drug imports, with increases discussed reaching one hundred percent.
"This agreement with the United Kingdom bolsters the worldwide climate for new treatments and brings long-overdue fairness to U.S.–U.K. pharmaceutical trade," an announcement noted.
Commercial Importance
Medicines are one of the Britain's biggest goods shipped to the America, which is clearly the biggest destination for major companies like GSK and AstraZeneca.
Statistics show that in the one-year period leading up to September, the UK shipped pharmaceutical products worth billions to the US. This figure accounted for a significant portion of all goods exports in that span.
"This deal protects employment, increases capital expenditure and sets the stage for the UK to become a global hub for life sciences," the Business and Trade Secretary commented.
Specific UK Commitments
The deal includes several key commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it deems new treatments to be too expensive by a quarter.
- Higher Drug Budget: There is a goal to increase overall NHS spending on medicines from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Refund Ceiling: The sum pharmaceutical firms must return to the NHS to stay within budget will be capped at 15%. Last year, rebates topped 20%.
Recent Tensions
This agreement comes amid a protracted dispute between the drug companies and the ministers over spending levels and regulatory access.
These tensions were intensified by arguments that US patients were paying several times more for the same drugs than patients in the UK and Europe.
Recently, several major pharmaceutical investments in the UK have been delayed or abandoned, while multi-billion-dollar investments have been announced toward American operations.
One official acknowledged that the NHS must increase expenditure on medicines, noting that its spending on drugs had decreased as a percentage of its total funding over the last ten years.
